What is Vivos Therapeutics Gross-Profit-to-Asset %?
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Vivos Therapeutics's annualizedGross Profit for the quarter that ended in Mar. 2024 was $7.75 Mil.
Vivos Therapeutics's average Total Assets over the quarter that ended in Mar. 2024 was $11.27 Mil. Therefore, Vivos Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 68.77%.
Vivos Therapeutics Gross-Profit-to-Asset % Historical Data
The historical data trend for Vivos Therapeutics's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Vivos Therapeutics's Gross-Profit-to-Asset %
For the Medical Devices subindustry, Vivos Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivos Therapeutics's Gross-Profit-to-Asset % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vivos Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Vivos Therapeutics's Gross-Profit-to-Asset % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Mar. 2024) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Vivos Therapeutics Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of Vivos Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Vivos Therapeutics (Vivos Therapeutics) Business Description
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VVOS has been successfully added to your 